Table 1.
Summary of patient characteristics.
| At baseline | |
| Number of patients/eyes | 11/22 |
| Sex (male: female) | 0 : 11 |
| Age (yrs), mean (SD) | 45.4 (19.1) |
| Location of lesion | Only ON 8 cases, ON + myelitis and encephalitis 3 cases |
| Antibodies | AQP4 antibody: 9 cases |
| MOG antibody: 3 cases | |
| Double positive: 1 case | |
|
| |
| At the initiation of immunosuppressive therapy | |
| Mean age, years (SD) | 42.5 (19.7) |
| Mean number of ON attack episodes (SD) | 1.7 (1.0) |
| Mean number of myelitis and encephalitis episodes (SD) | 0.7 (1.4) |
| Median follow-up period before start of immunosuppressive therapy, years (first-third quartile) | 1.8 (0.8–5.2) |
|
| |
| Types of treatments (number of patients) | |
| Only methylprednisolone | 4 |
| Methylprednisolone + plasma exchange | 4 |
| Methylprednisolone + intravenous immunoglobulin | 2 |
| Methylprednisolone + intravenous immunoglobulin + plasma exchange | 1 |
SD: standard deviation, ON: optic neuritis, AQP4: anti-aquaporin4 antibody, MOG: anti-myelin oligodendrocyte glycoprotein MP: methylprednisolone, PE: plasma exchange, IVIg: intravenous immunoglobulin.